1. Home
  2. AGIO vs PLUS Comparison

AGIO vs PLUS Comparison

Compare AGIO & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • PLUS
  • Stock Information
  • Founded
  • AGIO 2007
  • PLUS 1990
  • Country
  • AGIO United States
  • PLUS United States
  • Employees
  • AGIO N/A
  • PLUS N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • PLUS Retail: Computer Software & Peripheral Equipment
  • Sector
  • AGIO Health Care
  • PLUS Technology
  • Exchange
  • AGIO Nasdaq
  • PLUS Nasdaq
  • Market Cap
  • AGIO 2.3B
  • PLUS 1.9B
  • IPO Year
  • AGIO 2013
  • PLUS 1996
  • Fundamental
  • Price
  • AGIO $36.78
  • PLUS $73.84
  • Analyst Decision
  • AGIO Buy
  • PLUS
  • Analyst Count
  • AGIO 6
  • PLUS 0
  • Target Price
  • AGIO $57.00
  • PLUS N/A
  • AVG Volume (30 Days)
  • AGIO 779.8K
  • PLUS 148.5K
  • Earning Date
  • AGIO 10-30-2025
  • PLUS 11-11-2025
  • Dividend Yield
  • AGIO N/A
  • PLUS 1.35%
  • EPS Growth
  • AGIO N/A
  • PLUS 9.38
  • EPS
  • AGIO 11.13
  • PLUS 4.46
  • Revenue
  • AGIO $40,875,000.00
  • PLUS $2,170,452,000.00
  • Revenue This Year
  • AGIO $28.19
  • PLUS $7.12
  • Revenue Next Year
  • AGIO $152.14
  • PLUS N/A
  • P/E Ratio
  • AGIO $3.31
  • PLUS $17.66
  • Revenue Growth
  • AGIO 30.57
  • PLUS N/A
  • 52 Week Low
  • AGIO $23.42
  • PLUS $53.83
  • 52 Week High
  • AGIO $62.58
  • PLUS $106.98
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 48.43
  • PLUS 58.13
  • Support Level
  • AGIO $34.97
  • PLUS $70.02
  • Resistance Level
  • AGIO $37.91
  • PLUS $74.88
  • Average True Range (ATR)
  • AGIO 1.67
  • PLUS 1.85
  • MACD
  • AGIO -0.21
  • PLUS 0.13
  • Stochastic Oscillator
  • AGIO 48.57
  • PLUS 82.10

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

Share on Social Networks: